GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » 3-Year ROIIC %

Cadrenal Therapeutics (Cadrenal Therapeutics) 3-Year ROIIC % : 0.00% (As of )


View and export this data going back to 2023. Start your Free Trial

What is Cadrenal Therapeutics 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Cadrenal Therapeutics does not have enough data to calculate 3-Year ROIIC %.


Cadrenal Therapeutics 3-Year ROIIC % Historical Data

The historical data trend for Cadrenal Therapeutics's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadrenal Therapeutics 3-Year ROIIC % Chart

Cadrenal Therapeutics Annual Data
Trend Dec22 Dec23
3-Year ROIIC %
- -

Cadrenal Therapeutics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Cadrenal Therapeutics's 3-Year ROIIC %

For the Biotechnology subindustry, Cadrenal Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cadrenal Therapeutics's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadrenal Therapeutics's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Cadrenal Therapeutics's 3-Year ROIIC % falls into.



Cadrenal Therapeutics 3-Year ROIIC % Calculation

Cadrenal Therapeutics's 3-Year ROIIC % for the quarter that ended in is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( () - () )/( () - () )
=/
=N/A%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Cadrenal Therapeutics  (NAS:CVKD) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Cadrenal Therapeutics 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Cadrenal Therapeutics's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cadrenal Therapeutics (Cadrenal Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Executives
John Raymond Murphy director 233 S PATTERSON AVE, SPRINGFIELD MO 65802
Quang X Pham director, 10 percent owner, officer: CEO and Chairman 89 MELROSE DRIVE, MISSION VIEJO CA 92692
Robert Lisicki director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Douglas W Losordo officer: Chief Medical Officer 13 FOX MEADOW RD, SCARSDALE NY 10583
Steven Zelenkofske director 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Matthew K Szot officer: Chief Financial Officer 802 NORTH DOUTY STREET, HANFORD CA 93230
Glynn Wilson director 2483 NE JULEP STREET, ISSAQUAH WA 98029